Anzai 2020.
Study characteristics | ||
Study design | Mathematical modelling study
|
|
Disease | COVID‐19 | |
Travel‐related control measure(s) | Multiple measures
Date of implementation: January 23 2020 |
|
Country implementing the measure(s) | Country protected by the measure: n.r./Japan for outcome 2 Country restricted by the measure: China |
|
Outcome(s) | Cases avoided due to the measure
Shift in epidemic development
Shift in epidemic development
|
|
Notes | COI: “The authors declare no conflicts of interest.” Funding: “H.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers, H.N.: 17H04701, 17H05808, 18H04895 and 19H01074; R.K.: 18J21587; AS.: 19K24159], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413]. SMJ and NML receive graduate study scholarships from the Ministry of Education, Culture, Sports, Science and Technology, Japan.” |